港股異動 | 新秀麗連續2日反彈 大摩認為其風險回報具吸引力
格隆匯11月7日丨新秀麗(1910.HK)再度拉昇漲超5%,2累計漲幅達12%,報18.82港元,總市值270億港元。數據顯示,該股在10月31日獲摩根大通增持190.97萬股,涉資約3203.9萬港元。大摩在10月底發佈研究報吿稱,予新秀麗“增持”評級,預計未來30日股價將升,發生機率或達70%至80%,目標價26.1港元,認為其風險回報具吸引力,預將會是少數幾間有可能在未來1-2季內實現上調預測的消費類公司之一。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.